Floatz logo

OTL-38

Ovarian Cancer

On Target Laboratories, LLCSmall moleculePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
59/ 100

Competitive context

524 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
Inno-206
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

OTL-38 is also rated in:

lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
childhood malignant neoplasmDormant
B
Indicative ·
60 / 100
View asset →
Childhood Malignant Thoracic NeoplasmDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →